Related Experiment Video
Updated: Mar 29, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer
Background:
S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient.
Methods:
Eligibility criteria were no prior chemotherapy, stage IIIB or IV NSCLC, performance status 0-1, age >70 years, and adequate hematological, hepatic, and renal functions. Patients received S-1 (40 mg/m(2) twice a day) for 28 consecutive days. This schedule was repeated every 6 weeks. The primary end point was the tumor response rate.
Results:
Thirty-two patients were enrolled and 31 patients were evaluable for response. The patients' median age was 80 years (range: 71-88). The response rate was 22.6% (95% CI: 11-38). Neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea of grade ≥ 3 occurred in 6, 6, 10, 3, and 3%, respectively.
Conclusions:
In elderly patients with previously untreated advanced NSCLC, S-1 appears to be well tolerated and demonstrates encouraging activity.
Insights
S-1 chemotherapy shows promising activity and good tolerability in elderly patients with advanced non-small cell lung cancer (NSCLC). This study evaluated S-1 for previously untreated patients over 70 years old.
Area of Science:
- Oncology
- Pharmacology
Background:
- S-1 is an oral fluoropyrimidine with demonstrated efficacy in non-small cell lung cancer (NSCLC).
- Limited data exist regarding S-1's use in elderly NSCLC patients.
Purpose of the Study:
- To evaluate the efficacy and tolerability of S-1 in elderly patients with advanced NSCLC.
- To determine the tumor response rate in this patient population.
Main Methods:
- A study included patients over 70 years old with stage IIIB or IV NSCLC and no prior chemotherapy.
- Patients received S-1 orally for 28 days every 6 weeks.
- The primary endpoint was the tumor response rate.
Main Results:
- Thirty-one evaluable patients with a median age of 80 years were included.
- The overall response rate was 22.6% (95% CI: 11-38).
- Grade ≥ 3 neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea occurred in 6%, 6%, 10%, 3%, and 3% of patients, respectively.
Conclusions:
- S-1 demonstrates encouraging activity in elderly patients with previously untreated advanced NSCLC.
- S-1 appears to be well tolerated in this specific patient group.
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:11Clinical Trials: Overview
02:56Treatment Resistent Cancers